Indivior Pharmaceuticals, Inc.
Macquarie said global biotech funding for the year through Aug. 7 rose 75% YoY, driven by IPOs up 235% and follow-ons up 138%. The XBI biotech index gained 7% in the week to Aug. 7. Braveheart Bio’s upsized IPO raised $382.5M and shares jumped 66%. Curium agreed to buy Lantheus for up to $8B, and Supernus and Indivior plan an all-stock merger.
Anderson Woodrow D (Chief Accounting Officer) purchased 1,500 shares of Indivior Pharmaceuticals, Inc. (INDV) at $36.28 on 2026-08-05.
Indivior Pharmaceuticals (NASDAQ:INDV) reported Q2 2026 adjusted EPS of $1.15 vs $0.74 expected, and revenue of $343 million vs $284.9 million expected. SUBLOCADE net revenue rose 21% to $253 million. Indivior raised FY2026 revenue guidance to $1.295B-$1.365B and SUBLOCADE guidance to $1.01B-$1.05B. Shares rose 9.22% premarket.
Over the past 7 days, alphai's AI scored 1 news story mentioning INDV (Indivior Pharmaceuticals, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent INDV coverage spans mergers & acquisitions, insider activity and earnings.
In the last 30 days, INDV insiders filed 1 SEC Form 4 transaction — 1 purchase ($54K) and no sales. The most active reporter was Anderson Woodrow D, Chief Accounting Officer, with 1 filing.
For INDV, the trade centers on deal-premium expectations in an all-stock structure and the probability of achieving synergies.
This is an insider open-market purchase, which can be read as mild positive sentiment but is not a fundamental catalyst by itself.
Raised 2026 guidance tied to record SUBLOCADE sales and higher patient starts increases confidence in sustained OUD franchise momentum.
The premium and expected close window are central for INDV holders, but regulatory approvals remain the main uncertainty.
Near-term trading likely dominated by merger mechanics and deal overhang, despite an earnings beat and strong Sublocade performance.
alphai scores every news story that mentions INDV with an AI model for sentiment and relevance, and aggregates insider trades from Indivior Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Macquarie said global biotech funding for the year through Aug. 7 rose 75% YoY, driven by IPOs up 235% and follow-ons up 138%. The XBI biotech index gained 7% in the week to Aug. 7. Braveheart Bio’s upsized IPO raised $382.5M and shares jumped 66%. Curium agreed to buy Lantheus for up to $8B, and Supernus and Indivior plan an all-stock merger.
6 min readAnderson Woodrow D (Chief Accounting Officer) purchased 1,500 shares of Indivior Pharmaceuticals, Inc. (INDV) at $36.28 on 2026-08-05.
1 min readIndivior Pharmaceuticals (NASDAQ:INDV) reported Q2 2026 adjusted EPS of $1.15 vs $0.74 expected, and revenue of $343 million vs $284.9 million expected. SUBLOCADE net revenue rose 21% to $253 million. Indivior raised FY2026 revenue guidance to $1.295B-$1.365B and SUBLOCADE guidance to $1.01B-$1.05B. Shares rose 9.22% premarket.
4 min readSupernus Pharmaceuticals and Indivior agreed to merge in a deal valued at about $1.8 billion. Indivior shareholders will receive 0.2683 Supernus shares each, a stated ~58% premium. Supernus shareholders will own ~58% and Indivior ~42%. Closing is expected in H2 2026, pending approvals, with ~$125 million annual cost synergies by end-2027.
3 min readIndivior (INDV) agreed to a tax-free, all-stock merger with Supernus (SUPN). Indivior shareholders will own about 56.5% and Supernus 43.5%. The combined CNS-focused company is expected to close in Q4 2026 and trade on Nasdaq under SUPN. Pro forma: ~$2.2B revenue, $888M adjusted EBITDA, $125M synergies. Indivior Q2 2026: adj. EPS $1.15, revenue $343M.
7 min readSupernus Pharmaceuticals and Indivior are planning an all-stock merger to form a CNS-focused biopharma. The deal is expected to produce pro forma net revenue of $2.2bn and about $125m in annual cost synergies. Supernus brings Qelbree and Gocovri; Indivior brings Sublocade, Suboxone and Opvee. If completed in Q4 2026, the combined firm will trade as SUPN on Nasdaq.
4 min readIndivior and Supernus outlined a proposed tax-free all-stock “merger of equals” between the two companies. Indivior plans to file an SEC Form S-4 with a joint proxy statement/prospectus, and both firms will submit additional SEC documents. Shareholders will receive the definitive joint proxy statement/prospectus when available.
3 min readSupernus Pharmaceuticals (SUPN) rose 3% after announcing a definitive, tax-free all-stock merger with Indivior Pharmaceuticals (INDV), expected to close in Q4 and subject to approvals. The combined portfolio would include 11 FDA-approved drugs. Supernus reported Q2 revenue up 32% to just over $219M, but a net loss of over $58M and a miss versus EPS profit estimates.
5 min readIndivior Pharmaceuticals and Artemis Merger Sub agreed to merge with Supernus Pharmaceuticals, with Supernus as the surviving company and a wholly owned subsidiary of Indivior. After the deal, Indivior will be renamed Supernus. Jack A. Khattar will become CEO and CFO Timothy C. Dec will serve as CFO, effective at closing.
4 min readUS stock index futures rose in premarket as oil fell and bond yields eased, helped by reports of US-Iran talks. S&P futures were up 0.5% and Nasdaq up 0.4%, with Mag 7 mostly higher. Notable movers included ATKR +27% on Prysmian’s $95/share bid, BMY +5% on AstraZeneca acquisition talks, and SRAD -14% after guidance cut.
7 min read
